Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 4;3(2):e001909.
doi: 10.1136/bmjopen-2012-001909. Print 2013.

Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review

Blossom Christa Maree Stephan  1 , Thais Minett, Emma Pagett, Mario Siervo, Carol Brayne, Ian G McKeith
Affiliations

Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review

Blossom Christa Maree Stephan et al. BMJ Open. .

Abstract

Objective: To describe how criteria for amnestic Mild Cognitive Impairment (aMCI) have been operationalised in randomised controlled clinical trials (RCTs).

Design: Systematic review.

Information sources: EMBASE, PubMed and PSYCHInfo were searched from their inception to February 2012. Electronic clinical trial registries were also searched (February 2012).

Study selection: RCTs were included where participant selection was made using Petersen et al-defined aMCI. There was no restriction on intervention type or the outcome tested.

Data extraction: For each trial, we extracted information on study design, demographics, exclusion criteria and the operationalisation strategy for the five aMCI diagnostic criteria including: (1) memory complaint, (2) normal general cognitive function, (3) memory impairment, (4) no functional impairment and (5) no dementia.

Results: 223 articles and 278 registered trials were reviewed, of which 22 met inclusion criteria. Various methods were applied for operationalising aMCI criteria resulting in variability in participant selection. Memory complaint and assessment of general cognitive function were the most consistently measured criteria. There was large heterogeneity in the neuropsychological methods used to determine memory impairment. It was not possible to assess the impact of these differences on case selection accuracy for dementia prediction. Further limitations include selective and unclear reporting of how each of the criteria was measured.

Conclusions: The results highlight the urgent need for a standardised approach to map aMCI. Lack of uniformity in clinical diagnosis, however, is not exclusively a problem for MCI but also for other clinical states such as dementia including Alzheimer's disease, Lewy Body, frontotemporal or vascular dementia. Defining a uniform approach to MCI classification, or indeed for any classification concept within the field of dementia, should be a priority if further trials are to be undertaken in the older aged population based on these concepts.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Petersen criteria for amnestic Mild Cognitive Impairment.
Figure 2
Figure 2
PRISMA (2009) flow diagram of article selection.
See this image and copyright information in PMC

References

    1. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2003;2:646–53 - PubMed
    1. Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011;76:280–6 - PMC - PubMed
    1. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–8 - PubMed
    1. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–92 - PubMed
    1. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. - PMC - PubMed

LinkOut - more resources